LI Xing, ZHANG Bo-ya, LU Li-ting, WANG Yan, WEN Shuai, ZANG Yong-jun, XU Xiang-ming, MOU Yi. Research progress on the roles and inhibitors of deubiquitinase USP28 in tumorsJ. Acta Pharmaceutica Sinica, 2024, 59(11): 2941-2952. DOI: 10.16438/j.0513-4870.2024-0098
Citation: LI Xing, ZHANG Bo-ya, LU Li-ting, WANG Yan, WEN Shuai, ZANG Yong-jun, XU Xiang-ming, MOU Yi. Research progress on the roles and inhibitors of deubiquitinase USP28 in tumorsJ. Acta Pharmaceutica Sinica, 2024, 59(11): 2941-2952. DOI: 10.16438/j.0513-4870.2024-0098

Research progress on the roles and inhibitors of deubiquitinase USP28 in tumors

  • The deubiquitinases (DUBs), as the crucial peptidohydrolases in the ubiquitin system, can reverse and strictly regulate ubiquitination and play key roles in various biological processes, including the regulation of protein stability, cell signal transduction. Ubiquitin-specific protease 28 (USP28) involves multiple cancer-related signaling pathways by enhancing the stability of various cancer-related proteins, and is closely associated with the progression of colorectal, breast cancer, lung carcinomas, and pancreatic cancer. USP28 has been considered as a promising drug target in anticancer therapy, and the development of USP28 inhibitors has made some progress. In this article, we review the structure of USP28 and its interaction with substrates, discuss the research progress of USP28 in cancers and summarize the development of USP28 inhibitors.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return